Sponsor content

TheraMAB starts oncology clinical program with its mAb targeting an immune checkpoint

Tumor cells use various strategies to avoid immune reactions. Most efforts by researchers to circumvent these tactics have focused on monoclonal antibodies (mAbs) that target inhibitory checkpoints to reactivate the immune response against tumor cells. The rapidly growing field of immuno-oncology has seen the approval of several promising drugs of this kind.

Go to the profile of TheraMAB
Mar 01, 2017
0
0
Upvote 0 Comment
Page of

No comments yet.